Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
- Announced Encouraging Initial Clinical Data From the Phase 1/2 pheNIX PKU Gene Therapy Trial and Expects to Select Dose for Randomized, Concurrently Controlled Expansion Part Mid-Year 2020 - -...
-
BEDFORD, Mass., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today participation and presentations at the following investor and...
-
- Data Demonstrate AAVHSCs Crossed the Blood-Brain-Barrier and Blood-Nerve-Barrier, Produced Normal Levels of Human Protein and Reduced Key Biochemical Markers of Disease in Preclinical Models - ...
-
- Well-Tolerated in First-in-Human AAVHSC Gene Therapy Trial - - Preliminary Data from First Patient in Second Cohort Showed Dose-Response with Observed Reductions from Baseline in Phe and Phe/Tyr...
-
These Data Highlight Unmet Medical Need for Therapies to Control Phe Concentrations by Targeting the Underlying Cause of PKU BEDFORD, Mass., Dec. 16, 2019 (GLOBE NEWSWIRE) -- Homology Medicines,...
-
- Experienced Clinical Geneticist with Track Record in Rare Disease Drug Development Joins Homology’s Senior Management - BEDFORD, Mass., Dec. 03, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc....
-
BEDFORD, Mass., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today a peer-reviewed publication demonstrating its proprietary...
-
Expects to Report Initial Clinical Data from Phase 1/2 pheNIX PKU Gene Therapy Clinical Trial by Year-End Presented Preclinical Data Demonstrating Progress in MLD Gene Therapy and PKU Gene Editing...
-
BEDFORD, Mass., Oct. 25, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the oral presentation of preclinical data related to its...
-
BEDFORD, Mass., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the presentation of preclinical data that support its...